Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

In the mid-1980s, new molecular tools enabled the biology of cytokine expression and regulation to be studied. Our group uncovered a TNF-dependent cascade in active rheumatoid synovium, suggesting that TNF might be a therapeutic target; this concept was supported in an animal model of the disease. The proof of concept was a series of clinical trials, which have led to marked changes in the therapy of human rheumatoid arthritis and subsequently of other diseases. The work with TNF clearly demonstrated the importance of cytokines in medicine as well as the capacity of mAbs (or receptor fusion proteins) to be used long-term in large populations, thus changing the therapeutic landscape.

Original publication

DOI

10.4049/jimmunol.1090051

Type

Journal article

Journal

J Immunol

Publication Date

15/07/2010

Volume

185

Pages

791 - 794

Keywords

Animals, Antibodies, Monoclonal, Antirheumatic Agents, Arthritis, Rheumatoid, Clinical Trials as Topic, Drug Therapy, Combination, Humans, Infliximab, Methotrexate, Treatment Outcome, Tumor Necrosis Factor-alpha